The global inhibitor of nuclear factor-kappa b kinase subunit beta or IKK? market is expected to grow at a significant CAGR during the forecast period (2022-2028). IKK?, or inhibitor of nuclear factor kappa-B kinase subunit beta, is a protein encoded by the IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta) gene in humans. The IKK?, a particular regulator of nuclear factor-B (NF-B), is thought to be a promising target for developing new medications to treat rheumatoid arthritis and cancer.
To Request a Sample of our Report on Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market: https://www.omrglobal.com/request-sample/Inhibitor-of-nuclear-factor-kappa-b-kinase-subunit-beta-market
IKK? has been proven to be a therapeutic target for a variety of clinical illnesses, including cancer and chronic inflammatory diseases. Inflammation is present in a wide range of disorders and circumstances, including diseases. Allergies, asthma, autoimmune disorders, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, preperfusion damage, and transplant rejection are only few of the conditions that can occur. The rising prevalence of cancer across the globe is contributing to the growth of the global IKK? market. Breast and lung cancers were the most frequent cancers globally in 2020, accounting for 12.5% and 12.2% of all new cases, respectively. With 1.9 million new cases in 2020, colorectal cancer was the third most frequent cancer, accounting for 10.7% of all new cases. Lung cancer was the most frequent cancer in men globally in 2020, accounting for 15.4% of all new cases diagnosed. Lung, prostate, and colorectal cancers accounted for 41.9% of all cancer cases (excluding non-melanoma skin cancer). Other prevalent tumours that contributed more than 5% were stomach and liver cancers. Breast cancer was the most common cancer among women globally in 2020, accounting for 25.8% of all new cases diagnosed. Breast, colorectal, and lung cancers accounted for 44.5% of all cancer cases (excluding non-melanoma skin cancer). Cervical cancer was the fourth most frequent cancer among women in 2020, accounting for 6.9% of all new cases diagnosed.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Product
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Daiichi Sankyo Co Ltd., and EntreChem, S.L., among others.
(Get 15% Discount on Buying this Report)
A full Report of Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market is Available @ https://www.omrglobal.com/industry-reports/Inhibitor-of-nuclear-factor-kappa-b-kinase-subunit-beta-market
Global Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market Report by Segment
By Product
- TLX-1423
- IMD-0560
- EC-70124
- Others
By Application
- Colorectal Cancer
- Pancreatic Cancer
- Prostate Cancer
- Others
Global Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
